ETS-GS, a new anti-oxidative drug, protects against lipopolysaccharide-induced acute lung and liver injury

The Journal of Surgical Research
Satoshi HagiwaraTakayuki Noguchi

Abstract

Sepsis is a major health threat that remains refractory to treatment. Impairment of normal cellular function due to oxidative stress is implicated in organ injury during systemic inflammatory responses. We investigated whether the new anti-oxidative drug, ETS-GS, could inhibit secretion of cytokines and mono-nitrogen oxides, thus reducing organ damage in a rat model of lipopolysaccharide-induced sepsis. Lipopolysaccharide was administered intravenously to male Wistar rats in order to establish a rat model of systemic inflammation. These rats were challenged with or without intravenous ETS-GS. Mouse macrophage RAW264.7 cells were stimulated with lipopolysaccharide, with or without simultaneous ETS-GS treatment, in order to elucidate the mechanism of action. Histologic examination revealed that ETS-GS markedly reduced lipopolysaccharide-induced interstitial edema and leukocytic infiltration in lung tissue, and lipopolysaccharide-induced bleeding and leukocytic infiltration in liver tissue harvested 12 h after treatment. Cytokine (interleukin-6 and tumor necrosis factor-α) secretion was strongly induced by lipopolysaccharide; this induction was similarly inhibited by ETS-GS treatment. Likewise, lipopolysaccharide-induced secretion...Continue Reading

References

Jun 9, 1988·The New England Journal of Medicine·H R MichieD W Wilmore
Oct 1, 1982·Analytical Biochemistry·L C GreenS R Tannenbaum
Aug 14, 1999·Critical Care Medicine·R S HotchkissI E Karl
Mar 1, 2000·British Medical Bulletin·G Bellingan
Jun 3, 2000·Annual Review of Immunology·M Karin, Y Ben-Neriah
Nov 1, 2000·Critical Care Medicine·J A RussellK R Walley
Feb 17, 2001·American Journal of Respiratory and Critical Care Medicine·C SittipuntT R Martin
Dec 18, 2001·Pharmacology & Therapeutics·F FeihlL Liaudet
Feb 19, 2002·Kidney International·Michael S GoligorskyEisei Noiri
Dec 12, 2002·Chest·John D LangSadis Matalon
May 13, 2003·Chest·Stanley A Nasraway
Jan 27, 2004·The Journal of Pathology·Madhav Bhatia, Shabbir Moochhala
Sep 1, 2007·Inflammatory Bowel Diseases·Thomas Karrasch, Christian Jobin
Sep 13, 2008·Free Radical Biology & Medicine·Prabhanshu TripathiNaveen Arora
Jan 13, 2009·International Immunopharmacology· Mi Jeong Sung Dae Young Kwon
May 27, 2009·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Tapan M BhavsarCesar A Lau-Cam

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

© 2021 Meta ULC. All rights reserved